Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted) (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) reported EPS (Weighted Average and Diluted) of $0.25 for Q1 2026, up 56.25% on a YoY basis from $0.16 in Q1 2025, and down 83.66% quarter-over-quarter from $1.53 in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at $0.25 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 56.25% year-over-year to $0.25; the trailing twelve-month figure through Mar 2026 stood at $2.17 (up 675.0% YoY), and the FY2025 full-year result was $2.07, up 5075.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.25, down from $1.53 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.53 in Q4 2025, with the low at -$0.27 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.06 across 5 years, with a median of -$0.06 in 2022.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) sank 50.0% — and 2025, when it soared 15200.0%.
- Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.18 in 2022, then retreated by 5.56% to -$0.19 in 2023, then jumped by 105.26% to $0.01 in 2024, then soared by 15200.0% to $1.53 in 2025, then plunged by 83.66% to $0.25 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.25 (Q1 2026), $1.53 (Q4 2025), and $0.23 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Aurinia Pharmaceuticals | 2.18 Bn | 1.80 Bn | 71.20 Mn | 0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.25 |
| Dec 31, 2025 | 1.53 |
| Sep 30, 2025 | 0.23 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.16 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.10 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | -0.07 |
| Dec 31, 2023 | -0.19 |
| Sep 30, 2023 | -0.09 |
| Jun 30, 2023 | -0.08 |
| Mar 31, 2023 | -0.18 |
| Dec 31, 2022 | -0.18 |
| Sep 30, 2022 | -0.06 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.27 |
| Dec 31, 2021 | -0.25 |
| Sep 30, 2021 | -0.39 |
| Jun 30, 2021 | -0.37 |